Axogen

AXGN

Börsenwert 2,03 Mrd. $

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better bang for their buck right now?

ALACHUA, Fla. and TAMPA, Fla.

The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

ALACHUA, Fla. and TAMPA, Fla.

Biotech and specialty health care stocks can be attractive speculations because product innovation can drive explosive growth and attract intense takeover interest from large pharmaceutical companies. The challenge is determining which ones justify the risk, because early-stage drug developers are numerous, and many remain cash-burning for years.

Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.

Medical-device stocks Cooper Companies Inc (NASDAQ:COO) and Axogen Inc (NASDAQ:AXGN) are both sharply lower following separate company developments, and options traders are chiming in.

Axogen, Inc. (AXGN) M&A Call Transcript

ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an underwritten public offering of 4,910,000 shares of its common stock at a price to the public of $42.50 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition, Axogen has granted the underwriters a 30-day option to purchase up to an additional 736,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Axogen from the proposed offering, before deducting underwriters' discounts and commissions and other offering expenses payable by Axogen, are expected to be approximately $208.7 million (assuming no exercise of the underwriters' option to purchase additional shares). The proposed offering is expected to close on September 11, 2026, subject to the satisfaction of customary closing conditions.

Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen's addressable market within its focus markets